EUCTR2007-000490-40-ES进行中（未招募）不适用
Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function.Estudio de Cohortes Secuenciales, Aleatorizado, Doble Ciego,Controlado con Placebo y Multicéntrico para evaluar el Efecto de SLV320 añadido al tratamiento crónico con Furosemida sobre la función renal en pacientes con Insuficiencia Cardiaca Congestiva y Función Renal Alterada
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria to be included in the study:
- •1.Men and women aged 18 years to 85 years.
- •2.Informed consent must be obtained from each subject before any study-related procedure is performed.
- •3.Subjects must have a history of chronic, symptomatic NYHA Class II-III CHF and impaired renal function (baseline eGFR of 20 to 75 mL/min/1.73m2) for at least 3 months before Visit 1 (Day 1).
- •The Modification of Diet in Renal Disease (MDRD) equation to estimate GFR can be found on page 37 of the protocol (22 Mar 2007)
- •4.Subjects must be on chronic treatment with furosemide =40 mg daily for at least 3 weeks before Visit 1 (Day 1).
- •5.Subjects should be receiving optimal doses of standard CHF therapies (for example ACE inhibitors, beta-blockers, angiotensin receptor blockers (ARB), hydralazine, isosorbide dinitrate and/or digitalis). Subjects must have been on a stable dose of these medications for at least 4 weeks before Visit 1 (Day 1). Subjects receiving hydralazine and/or isosorbide dinitrate should have been treated with these drugs for at least 3 months before Visit 1 (Day 1).
- •Subjects should be taking both an ACE inhibitor (or ARB) and a beta-blocker, unless there is intolerance or a contraindication or another medical reason, which must be documented. Subjects should have been treated with these drugs for at least 3 months before Visit 1 (Day 1). They must also have been taking a stable dose for at least 4 weeks before Visit 1 (Day 1).
- •Subjects treated with amiodarone must also have been taking a stable dose for at least 4 weeks before Visit 1 (Day 1).
- •6.The subject must be male, female of non-childbearing potential or female of childbearing potential with an accepted birth control method.
- •Females with childbearing potential may be enrolled providing that:
- •-She is routinely using a medically accepted method of birth control. Medically accepted methods of birth control are defined as the use of either a contraceptive implant, a contraceptive injection, an intra-uterine device or an oral contraceptive for at least 3 months before Visit 1 (Day 1), and which she agrees to continue using during the study, or a double-barrier method which has to consist of a combination of any two of the following: diaphragm, cervical cap, condom, or spermicide.
- •-She agrees not to attempt at becoming pregnant during the study.
- •-A female of non-childbearing potential is defined as one who has been post-menopausal for at least 24 months, was surgically sterilized (bilateral tubal ligation) or had a hysterectomy prior to screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any female of childbearing potential without adequate contraception. Any female who is pregnant or breastfeeding.
- •2.The subject's condition is so unstable that he / she may require hospitalization (for cardiovascular disease) or adjustment of background medications for CHF.
- •3.Hospitalization within 7 days before Visit 1 (Day 1).
- •NB:A subject who was recently discharged from the hospital (less than 7 days) may not be randomized at that time, but may be reconsidered for Visit 1 (Day 1), after he / she is stabilized for at least 7 days.
- •4.Evidence of any significant respiratory, urogenital, gastro-intestinal, hepatic, hematological, immunologic, head, ears, eyes, nose, throat (HEENT), dermatologic, connective tissue, musculoskeletal, metabolic, nutritional, endocrine, neurological, psychiatric diseases, allergy, major surgery or other relevant diseases as revealed by history, physical examination and / or laboratory assessments which might limit participation in or completion of the study.
- •5.Recent or chronic gastro-intestinal, hepatic, or biliary disorder that could impair absorption, metabolism, or excretion of orally administered medication.
- •6.Subjects with malignant tumors with a short life expectancy and / or severe infection.
- •7.Concomitant use of other investigational drugs or use of any investigational agent within 30 days before Visit 1 (Day 1), and within at least 10 half-life times of that agent before Visit 1 (Day 1).
- •8.Any history of a severe abnormal medication reaction.
- •9.Subjects with fever of = 38°C.
- •10.Subjects with significant liver disease or with serum transaminase concentrations (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) more than three times the upper limit of the normal reference range.
- •11.Subjects with uncontrolled diabetes (fasting serum glucose > 11 mmol/L [> 197 mg/dL]).
- •12.Subjects with eGFR < 20 mL/min/1.73m2 calculated by the MDRD equation.
- •The MDRD equation to estimate GFR can be found on page 38 of the Protocol (Date: 22 Mar 2007)
- •13.Subjects with serum potassium < 3.5 mmol/L or > 5.5 mmol/L.
- •14.Subjects with hemoglobin of < 9 g/dL (< 90 g/L) or hematocrit of < 30%.
- •15.Subjects with bilateral renal artery stenosis (from medical history).
- •16.Any history of a convulsive disorder or pre-convulsive state and any risk for a convulsive disorder or pre-convulsive state (for example any past brain trauma, abuse of alcohol etcetera).
- •17.Subjects may not be related to the Investigator in any way (family relation, practice workers etcetera).
- •18.Inability to return for scheduled visits.
- •19.Any condition associated with poor compliance including alcoholism, mental illness or medication dependence. Inability of the subject to understand and follow the requirements of the protocol in the language of the Investigator.
- •20.Any other reason, in the Investigator’s opinion, that prohibits inclusion of the subject into the study.
研究者
相似试验
进行中（未招募）
不适用
Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function.EUCTR2007-000490-40-DESolvay Pharmaceuticals GmbH300
进行中（未招募）
不适用
Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function.Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function who are on Chronic Furosemide TreatmentMedDRA version: 9.1Level: LLTClassification code 10010684Term: Congestive heart failureEUCTR2007-000490-40-CZSolvay Pharmaceuticals GmbH300
进行中（未招募）
不适用
Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function.Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function who are on Chronic Furosemide TreatmentMedDRA version: 9.1Level: LLTClassification code 10010684Term: Congestive heart failureEUCTR2007-000490-40-BESolvay Pharmaceuticals GmbH300
撤回
2 期
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexatechronische gewrichtsaandoeninginflammation of the joints10003816NL-OMON34069Galapagos NV6
招募中
1 期
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)MedDRA version: 20.0Level: PTClassification code: 10052787Term: Migraine without aura Class: 100000004852MedDRA version: 20.0Level: PTClassification code: 10027607Term: Migraine with aura Class: 100000004852MedDRA version: 20.0Level: PTClassification code: 10027599Term: Migraine Class: 100000004852MedDRA version: 22.0Level: LLTClassification code: 10082019Term: Episodic migraine Class: 10029205MigraineCTIS2023-506029-12-00AbbVie Deutschland GmbH & Co. KG1,300